In the November issue of Pharmacogenomics 9(11), the following text appeared in the News & Views section in the article ‘Early results of PREDICT study give hope for novel pharmacoprediction model in growth hormone therapy‘ (Pharmacogenomics 9[11], 1579–1581 [2008]):
The global pharmaceutical company Merck Serono (Geneva, Switzerland) has announced the one-month results of its pharmacogenomics study Prospective Evaluation of Diabetic Ischemic heart disease by Computed Tomography, aimed at identifying genetic markers associated with variation in response to growth hormone (GH) treatment in children with GHD and TS. Representing one of the largest prospective studies ever conducted in the field, the findings will ultimately be used to develop a novel pharmacoprediction model to optimize GH therapy.
This should read:
The global pharmaceutical company Merck Serono (Geneva, Switzerland) has announced the one-month results of its pharmacogenomics study PREDICT. PREDICT is a Phase IV open-label study for predictive markers of response to treatment in pre-pubertal children with growth hormone deficiency (GHD) or Turner syndrome (TS) treated with Saizen® (somatropin), aiming at identifying genetic markers associated with variation in response to growth hormone (GH). Representing one of the largest prospective studies ever conducted in the field, the findings will ultimately be used to develop a novel pharmacoprediction model to optimize GH therapy.
And also:
GHD, in which the pituitary gland fails to produce sufficient growth hormone, is estimated to affect one in 4000 to one in 10,000 children. TS, caused by monosomy of chromosome X in females, affects around one in 2500 girls and manifests itself in a variety of ways including short stature.
This should read:
GHD, in which the pituitary gland fails to produce sufficient growth hormone, is estimated to affect one in 4000 to one in 10,000 children. TS, caused by monosomy or defect of chromosome X in females, affects around one in 2500 girls and manifests itself in a variety of ways including short stature.
The editors of Pharmacogenomics would like to sincerely apologize for any inconvenience or confusion this may have caused our readers.